The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with the society’s Transplant Infectious Diseases Special Interest Group to update its previous infectious disease guidelines for the prevention and management of cytomegalovirus (CMV) infection and disease following hematopoietic cell transplantation (HCT). The two updates, published in 2021, focused on the prevention and management of CMV infection, respectively, including refractory and resistant CMV infections. To best serve clinical providers, each standalone topic in the infectious diseases series has been published in a concise format of frequently asked questions (FAQs). Adult and pediatric infectious diseases and HCT content experts developed the FAQs and the answers; recommendations were graded according to their strength (A-E) and the level of the supporting evidence (I-III). Several advances in CMV prevention and management since 2021 warranted an update to the original third and fourth topics in the series.This eleventh topic in the series focuses on new antiviral treatments for CMV, expanded indications of existing antiviral therapy for the prevention of CMV, and the treatment of CMV in special populations such as CAR T-cell therapy recipients and pediatric transplant recipients.

美国移植与细胞治疗学会实践指南委员会与该学会的移植传染病特别兴趣小组合作，更新了其先前关于造血细胞移植（HCT）后巨细胞病毒（CMV）感染与疾病的预防和管理的传染病指南。2021年发布的这两项更新分别聚焦于CMV感染的预防和管理，包括难治性和耐药性CMV感染。

为了更好地服务临床医护人员，该传染病系列中的每个独立主题均以简明的常见问题（FAQs）形式发布。成人和儿童传染病及造血细胞移植领域的内容专家编写了这些常见问题及答案；推荐意见根据其强度（A-E级）和支持证据水平（I-III级）进行分级。

2021年以来，CMV预防和管理领域的多项进展使得有必要对该系列中原先的第三和第四个主题进行更新。本系列的第十一个主题聚焦于CMV的新型抗病毒治疗、现有抗病毒治疗在CMV预防中的适应症扩展，以及CAR-T细胞治疗受者和儿童移植受者等特殊人群的CMV治疗。